Senior Researcher
CurrentNEXEL is a world leader in iPSC (induced Pluripotent Stem Cell) technology as the first Korean company to license iPS technology and setting a new paradigm in the in vitro toxicity field through successful commercialization of iPS-derived cells which mimic actual human functionality. Furthermore, we are investing our expertise into the discovery and development of new drug candidates based on proteins and peptides derived from stem cell technology.